A Research Study to Look at How Semaglutide Works Compared to Placebo in People With Overweight or Obesity

Trial identity

Registry

ClinicalTrials.gov

Registry ID

NCT04184622

Phase

Phase 3

Design

Interventional

Allocation

Randomized

Masking

Double-blind

Overall status

Completed

Result status

published

Sponsors & collaborators

Sponsor

Novo Nordisk

Collaborators

—

Population & enrollment

Population summary

Adults with obesity or overweight with at least one weight-related comorbidity.

Eligibility summary

BMI ≥30 kg/m² or ≥27 kg/m² with comorbidity; without diabetes.

Planned enrollment

1961

Actual enrollment

1961

Endpoints

Primary endpoint

Percent change in body weight from baseline to week 68

Secondary endpoints

Proportion achieving ≥5%, ≥10%, ≥15%, ≥20% weight loss

Change in waist circumference

Dates

Start date

Jun 1, 2018

Primary completion

Nov 1, 2020

Completion date

Mar 1, 2021

Last synced

Aug 15, 2024

Plain-language interpretation

A Research Study to Look at How Semaglutide Works Compared to Placebo in People With Overweight or Obesity is a Phase 3 Interventional sponsored by Novo Nordisk. It is evaluating Semaglutide in Adults with obesity or overweight with at least one weight-related comorbidity.. The primary endpoint is Percent change in body weight from baseline to week 68.

Registry disclaimer: Information is derived from public registry records and may lag behind the official source. Always verify against ClinicalTrials.gov.